Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy
The combination of immunotherapy and antiangiogenic agents showed promising efficacy and acceptable toxicity in patients with aSTS, especially those with alveolar soft part sarcoma or clear cell sarcoma.
Authors
- Rui Bai (ORCID: https://orcid.org/0000-0002-3025-9975)
- Qunan Sun
- Ying Dong (ORCID: https://orcid.org/0009-0004-1656-6348)
- Haifeng Chen (ORCID: https://orcid.org/0000-0002-8181-7893)
- Youping Wang (ORCID: https://orcid.org/0000-0002-7119-782X)
- Shaoli Li (ORCID: https://orcid.org/0000-0002-3513-2359)
- Hui Wang (ORCID: https://orcid.org/0009-0006-3512-9308)
Institutions
- Zhejiang Cancer Hospital (CN)
- Shaoxing Second Hospital (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- University of Chinese Academy of Sciences (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1186/s12885-024-12810-9
- Citations
- 3
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26